Microfluidics announces PureNano as brand name of MRT technology
4 Feb 2011
Microfluidics has rebranded its innovative MRT nanoparticle
creation technology as the PureNano platform, featuring the PureNano
PureNano combines a unique machine with expert process development
to achieve smaller and more consistent particle sizes than
previously possible for many applications, especially within the
pharmaceutical and energy industries.
The PureNano Continuous Crystallizer provides research teams with
new tools and methods to create stable inhalable formulations,
improve the bioavailability of antibiotics and target delivery of
novel cancer treatments, among other possibilities. Additional
applications of PureNano include multi-phase chemical reactions and
"PureNano is a milestone achievement of innovation for our
company and represents a revolutionary and necessary step forward in
the evolution of continuous crystallization," said Michael C.
Ferrara, President and Chief Executive Officer of Microfluidics.
"Beta units in the field are surpassing the expectations of our
pharmaceutical customers, and we are excited to discover with them
the technology's full potential. In addition, our PureNano partners
— POWREX in Japan and Particle Sciences in the United States —
continue to commit to PureNano as a differentiator and an important
part of the future of nanomaterials processing."
PureNano/MRT is a globally-patent-pending technology with active
filings and applications in Australia, Canada, China, Europe, India,
Israel, Japan and the United States.
"Pharmaceutical companies are seeking solutions for continuous
crystallization using high shear, and PureNano fits this trend,"
said Mimi Panagiotou, PhD, Microfluidics Chief Technology Officer
and co-creator of the technology. "As a platform technology,
PureNano opens new avenues for improving drug bioavailability,
suspension stability and actives delivery for potential breakthrough